<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00744263</url>
  </required_header>
  <id_info>
    <org_study_id>6115A1-3006</org_study_id>
    <secondary_id>B1851025</secondary_id>
    <nct_id>NCT00744263</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults</brief_title>
  <acronym>CAPITA</acronym>
  <official_title>A Phase 4, Randomized, Placebo-Controlled Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine Efficacy in Prevention of Vaccine-Serotype Pneumococcal Community-Acquired Pneumonia and Invasive Pneumococcal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate
      vaccine in the prevention of the first episode of vaccine-type pneumococcal
      community-acquired pneumonia in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)</measure>
    <time_frame>Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
    <description>CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (&gt;) 38.0 degrees Celsius (C) or less than (&lt;) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (&gt;10*10^9 white blood cells/liter or &gt;15 percent (%) bands), C-reactive protein level &gt;3 times upper limit of normal, hypoxemia with partial oxygen pressure &lt;60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)</measure>
    <time_frame>Baseline up to occurrence of first episode of NB/NI VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
    <description>CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature &gt;38.0 degrees C or &lt;36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (&gt;10*10^9 white blood cells/liter or &gt;15% bands), C-reactive protein level &gt;3 times upper limit of normal, hypoxemia with partial oxygen pressure &lt;60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases</measure>
    <time_frame>Baseline up to occurrence of first episode of VT-IPD, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
    <description>VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination</measure>
    <time_frame>Within 7 days after vaccination</time_frame>
    <description>Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination</measure>
    <time_frame>Within 7 days after vaccination</time_frame>
    <description>Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain [new muscle/joint pain], aggravated generalized muscle/joint pain [aggravated muscle/joint pain], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(&lt;38 degrees C); Mild(greater than or equal to [&gt;=]38 to &lt;38.5 degrees C); Moderate(&gt;=38.5 to &lt;39 degrees C); Severe(&gt;=39 to less than or equal to [&lt;=]40 degrees C); Potentially life threatening (&gt;40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours [hrs]); Moderate(&gt;2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(&gt;=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants Who Died</measure>
    <time_frame>From signing of informed consent form up to case acquisition period defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
    <description>Deaths collected throughout the case acquisition period were presented.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Newly Diagnosed Chronic Medical Condition</measure>
    <time_frame>From 1 month after vaccination up to 6 months after vaccination</time_frame>
    <description>Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84496</enrollment>
  <condition>Pneumonia, Pneumococcal</condition>
  <condition>Pneumococcal Infections</condition>
  <condition>13-valent Pneumococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>13-valent pneumococcal conjugate vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VACCINE: placebo</intervention_name>
    <description>0.5 mL, single intra-muscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VACCINE: 13-valent pneumococcal conjugate vaccine</intervention_name>
    <description>0.5 mL, single intra-muscular injection</description>
    <arm_group_label>13-valent pneumococcal conjugate vaccine</arm_group_label>
    <other_name>13vPnC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female adults aged 65 years or older on the day of vaccination and able to
             fulfill study requirements.

        Exclusion Criteria:

          -  Previous vaccination with any licensed or experimental pneumococcal vaccine

          -  Residence in a nursing home, long-term care facility, or similar facility

          -  Known hypersensitivity to vaccination

          -  Immune deficiency or suppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <state>Noord Brabant</state>
        <zip>5022 JB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Abbekerk</city>
        <zip>1657 AH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1825 PV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1315 RA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Almere</city>
        <zip>1355 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Alphen aan de Rijn</city>
        <zip>2402 EP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3813 TZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amersfoort</city>
        <zip>3821 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amstelveen</city>
        <zip>1186 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amstelveen</city>
        <zip>1186 DA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1043 GR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1098 NJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7333 NS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Apeldoorn</city>
        <zip>7336 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6842 CT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Assen</city>
        <zip>9401 RK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Assen</city>
        <zip>9406 GT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baarle-Nassau</city>
        <zip>5111 BX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baarn</city>
        <zip>3743 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bedum</city>
        <zip>9781 JG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bennebroek</city>
        <zip>2121 AJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4611 RD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bergen op Zoom</city>
        <zip>4624 VT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berkel Enschot</city>
        <zip>5056 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berkhout</city>
        <zip>1647 ME</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bilthoven</city>
        <zip>3723 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Blaricum</city>
        <zip>1261 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4811 VC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Breda</city>
        <zip>4835 ND</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brunssum</city>
        <zip>6444 AT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Deventer</city>
        <zip>7418 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dongen</city>
        <zip>5104 JK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eelde</city>
        <zip>9761 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5600 HK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5611 ZB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5616 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5631 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Emmen</city>
        <zip>7811 HN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Emmen</city>
        <zip>7824 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Enschede</city>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Enschede</city>
        <zip>7521 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Epe</city>
        <zip>8162 BD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ettenleur</city>
        <zip>4876 AS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fijnaart</city>
        <zip>4793 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Geldrop</city>
        <zip>5664 EH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Geldrop</city>
        <zip>5664 EP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Geldrop</city>
        <zip>5664 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goirle</city>
        <zip>5051 RJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gouda</city>
        <zip>2803 AH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gouda</city>
        <zip>2803 PL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9733 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Grootebroek</city>
        <zip>1613 SJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Haarlem</city>
        <zip>2035 RJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Haren</city>
        <zip>9751 ND</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Harmelen</city>
        <zip>3481 EN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heerhugowaard</city>
        <zip>1701 GB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6412 CD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Heiloo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Helmond</city>
        <zip>5707 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 BB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hilvarenbeek</city>
        <zip>5081JV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <zip>1217 GP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hoogezand</city>
        <zip>9601 KE�</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1624 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1628 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hoorn</city>
        <zip>1642 NP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houten</city>
        <zip>3995 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kampen</city>
        <zip>8266 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Katwijk</city>
        <zip>2223 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kerkrade</city>
        <zip>6461 AL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leek</city>
        <zip>9351 KP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8915 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2316 XC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leiden</city>
        <zip>2334 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leiderdorp</city>
        <zip>2353 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maarssen</city>
        <zip>3603 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6227 BZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Medemblik</city>
        <zip>1671 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3439 ML</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6546 BC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Noordwijk</city>
        <zip>2202 NS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oldenzaal</city>
        <zip>7573 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oosterhout</city>
        <zip>4907 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Peize</city>
        <zip>9321 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rheden</city>
        <zip>6991 DV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Riel</city>
        <zip>5133 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rijsbergen</city>
        <zip>4891 XL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rijssen</city>
        <zip>7461DA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roden</city>
        <zip>9301 JL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roermond</city>
        <zip>6042EH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roermond</city>
        <zip>6043 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roermond</city>
        <zip>6043 WD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roosendaal</city>
        <zip>4700 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Roosendaal</city>
        <zip>4708 HK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Schoorl</city>
        <zip>1871 EE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Simpelveld</city>
        <zip>6369 AG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sittard</city>
        <zip>6131 KJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sittard</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sleen</city>
        <zip>7841 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Soest</city>
        <zip>3762 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Son</city>
        <zip>5691 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spaubeek</city>
        <zip>6176 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Steenbergen</city>
        <zip>4651 RN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tiel</city>
        <zip>4002 WP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 JB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uithoorn</city>
        <zip>1422 LE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Urmond</city>
        <zip>6129 EL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3524 SJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3525 AL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3527 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3565 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3582 KE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5500 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5503 VV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Velp</city>
        <zip>6883 AW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Venlo</city>
        <zip>5911HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Waalwijk</city>
        <zip>5141 BM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warmenhuizen</city>
        <zip>1749 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Weert</city>
        <zip>3001 BE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Woerden</city>
        <zip>3447 GN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zeist</city>
        <zip>3703 CD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zeist</city>
        <zip>3707 HL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zeist</city>
        <zip>3707 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zevenaar</city>
        <zip>6903 ZN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7201 NC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 BA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 BT</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6115A1-3006&amp;StudyName=Study%20Evaluating%20the%20effiacy%20of%20a%2013-Valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20in%20Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <results_first_submitted>October 1, 2014</results_first_submitted>
  <results_first_submitted_qc>October 1, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2014</results_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Of 84496 participants who were randomized in this study, 2011 participants were included in the immunogenicity subset. Participants in the immunogenicity subset were analyzed for local reactions and systemic events as per planned analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC</title>
          <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42240"/>
                <participants group_id="P2" count="42256"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37004"/>
                <participants group_id="P2" count="36936"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5236"/>
                <participants group_id="P2" count="5320"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3006"/>
                <participants group_id="P2" count="3005"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2038"/>
                <participants group_id="P2" count="2135"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="150"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received study vaccine and who had any safety data.</population>
      <group_list>
        <group group_id="B1">
          <title>13vPnC</title>
          <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42237"/>
            <count group_id="B2" value="42255"/>
            <count group_id="B3" value="84492"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.8" spread="5.7"/>
                    <measurement group_id="B2" value="72.8" spread="5.6"/>
                    <measurement group_id="B3" value="72.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18790"/>
                    <measurement group_id="B2" value="18454"/>
                    <measurement group_id="B3" value="37244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23447"/>
                    <measurement group_id="B2" value="23801"/>
                    <measurement group_id="B3" value="47248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)</title>
        <description>CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (&gt;) 38.0 degrees Celsius (C) or less than (&lt;) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (&gt;10*10^9 white blood cells/liter or &gt;15 percent (%) bands), C-reactive protein level &gt;3 times upper limit of normal, hypoxemia with partial oxygen pressure &lt;60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).</description>
        <time_frame>Baseline up to occurrence of first episode of VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
        <population>Per-protocol(PP) population: eligible participants who received study vaccine, 65 years or older, identified with CAP(pre-defined criteria) or had invasive pneumococcal disease(IPD); symptom onset at least 14 days after vaccination; immunocompetent at time of episode; no major protocol violations as determined by clinical scientist/medical monitor.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP)</title>
          <description>CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature greater than (&gt;) 38.0 degrees Celsius (C) or less than (&lt;) 36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (&gt;10*10^9 white blood cells/liter or &gt;15 percent (%) bands), C-reactive protein level &gt;3 times upper limit of normal, hypoxemia with partial oxygen pressure &lt;60 millimeter of mercury (mmHg). Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: VT Streptococcus pneumonia culture from blood, pleural fluid or other sterile site and/or positive VT serotype-specific urinary antigen detection (SSUAD).</description>
          <population>Per-protocol(PP) population: eligible participants who received study vaccine, 65 years or older, identified with CAP(pre-defined criteria) or had invasive pneumococcal disease(IPD); symptom onset at least 14 days after vaccination; immunocompetent at time of episode; no major protocol violations as determined by clinical scientist/medical monitor.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42240"/>
                <count group_id="O2" value="42256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against first event expressed as percentage. Vaccine efficacy = 1 - (proportion of participants who received 13vPnC with confirmed VT-CAP relative to those who received placebo). p-value and confidence intervals were derived using Clopper-Pearson method. The null hypothesis was vaccine efficacy = 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Clopper-Pearson method</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>45.56</param_value>
            <ci_percent>95.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.82</ci_lower_limit>
            <ci_upper_limit>62.49</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)</title>
        <description>CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature &gt;38.0 degrees C or &lt;36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (&gt;10*10^9 white blood cells/liter or &gt;15% bands), C-reactive protein level &gt;3 times upper limit of normal, hypoxemia with partial oxygen pressure &lt;60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.</description>
        <time_frame>Baseline up to occurrence of first episode of NB/NI VT-CAP, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
        <population>PP population: eligible participants who received study vaccine, 65 years or older, identified with CAP (pre-defined criteria) or had IPD; symptom onset at least 14 days after vaccination; immunocompetent at time of episode; no major protocol violations as determined by clinical scientist/medical monitor.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Episode of Nonbacteremic/Noninvasive (NB/NI) Vaccine-type Community-acquired Pneumonia (VT-CAP)</title>
          <description>CAP was defined based on clinical and radiological criteria. Microbiological criteria differentiate different categories of CAP. Clinical criteria: presence of 2 or more criteria from following: cough, production of purulent sputum/change in sputum character, temperature &gt;38.0 degrees C or &lt;36.1 degrees C, auscultatory findings consistent with pneumonia including rales and/or evidence of pulmonary consolidation, leukocytosis (&gt;10*10^9 white blood cells/liter or &gt;15% bands), C-reactive protein level &gt;3 times upper limit of normal, hypoxemia with partial oxygen pressure &lt;60 mmHg. Radiological criteria: pneumonia confirmation by adjudication committee via lateral, posterior-anterior chest x-ray or anterior-posterior chest x-ray. Microbiological criteria: Confirmed VT pneumococcal CAP (by SSUAD) where a blood culture result was available and was negative and for which any other sterile culture results were negative for Streptococcus pneumoniae.</description>
          <population>PP population: eligible participants who received study vaccine, 65 years or older, identified with CAP (pre-defined criteria) or had IPD; symptom onset at least 14 days after vaccination; immunocompetent at time of episode; no major protocol violations as determined by clinical scientist/medical monitor.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42240"/>
                <count group_id="O2" value="42256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against first event expressed as percentage. Vaccine efficacy = 1-(proportion of participants who received 13vPnC with confirmed VT-CAP relative to those who received placebo). p-value and confidence intervals were derived using Clopper-Pearson method. The null hypothesis was vaccine efficacy = 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0067</p_value>
            <method>Clopper-Pearson method</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>45.00</param_value>
            <ci_percent>95.2</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.21</ci_lower_limit>
            <ci_upper_limit>65.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases</title>
        <description>VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).</description>
        <time_frame>Baseline up to occurrence of first episode of VT-IPD, death, withdrawal of consent, loss to follow-up, participant request or end of case acquisition defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
        <population>PP population: eligible participants who received study vaccine, 65 years or older, identified with CAP (pre-defined criteria) or had IPD; symptom onset at least 14 days after vaccination; immunocompetent at time of episode; no major protocol violations as determined by clinical scientist/medical monitor.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Episodes of Vaccine-type Invasive Pneumococcal Disease (VT-IPD) Cases</title>
          <description>VT-IPD was defined as the presence of Streptococcus pneumoniae in a sterile site (blood, cerebrospinal fluid, pleural fluid, peritoneal fluid, pericardial fluid, surgical aspirate, bone, or joint fluid).</description>
          <population>PP population: eligible participants who received study vaccine, 65 years or older, identified with CAP (pre-defined criteria) or had IPD; symptom onset at least 14 days after vaccination; immunocompetent at time of episode; no major protocol violations as determined by clinical scientist/medical monitor.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42240"/>
                <count group_id="O2" value="42256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vaccine efficacy against first event expressed as percentage. Vaccine efficacy = 1-(proportion of participants who received 13vPnC with confirmed VT-CAP relative to those who received placebo). p-value and confidence intervals were derived using Clopper-Pearson method. The null hypothesis was vaccine efficacy = 0.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Clopper-Pearson method</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>75.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.43</ci_lower_limit>
            <ci_upper_limit>90.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination</title>
        <description>Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.</description>
        <time_frame>Within 7 days after vaccination</time_frame>
        <population>Immunogenicity subset included participants enrolled in the subset who received study vaccine, were able to complete e-diary and fulfilled other study procedures. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-specified Local Reactions Within 7 Days After Vaccination</title>
          <description>Local reactions were reported using electronic diary (e-diary). Redness and swelling scaled as Any (redness or swelling present); Absent (no or minimal); Mild (2.5 centimeter [cm] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (&gt;10.0 cm). Pain scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity). Limitation of arm movement scaled as Any (limitation present); Absent (no limitation of arm movement); Mild (some limitation of arm movement); Moderate (unable to move arm above head, but able to move arm above shoulder); Severe (unable to move arm above shoulder). Percentage of participants with local reactions were reported. Participants may be represented in more than 1 category.</description>
          <population>Immunogenicity subset included participants enrolled in the subset who received study vaccine, were able to complete e-diary and fulfilled other study procedures. Here 'N' (number of participants analyzed) signifies participants with known values for any local reaction and 'n' signifies participants with known values for specified local reaction.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="917"/>
                <count group_id="O2" value="867"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness: Any (n = 886, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.5" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.6" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n = 886, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="2.6" upper_limit="5.2"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n = 881, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.0" upper_limit="2.8"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n = 881, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.1" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n = 888, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="5.2" upper_limit="8.6"/>
                    <measurement group_id="O2" value="1.2" lower_limit="0.6" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n = 888, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="4.1" upper_limit="7.2"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n = 884, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="1.7" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n = 881, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Any (n = 914, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" lower_limit="33.0" upper_limit="39.3"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.6" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Mild (n = 913, 861)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="29.8" upper_limit="36.0"/>
                    <measurement group_id="O2" value="5.6" lower_limit="4.1" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Moderate (n = 886, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="6.0" upper_limit="9.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Severe (n = 881, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Any (n = 891, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" lower_limit="11.9" upper_limit="16.6"/>
                    <measurement group_id="O2" value="3.2" lower_limit="2.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Mild (n = 888, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="10.3" upper_limit="14.7"/>
                    <measurement group_id="O2" value="2.5" lower_limit="1.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Moderate (n =883, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.0" upper_limit="2.8"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Limitation of arm movement: Severe (n = 882, 861)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.6" upper_limit="2.2"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination</title>
        <description>Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain [new muscle/joint pain], aggravated generalized muscle/joint pain [aggravated muscle/joint pain], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(&lt;38 degrees C); Mild(greater than or equal to [&gt;=]38 to &lt;38.5 degrees C); Moderate(&gt;=38.5 to &lt;39 degrees C); Severe(&gt;=39 to less than or equal to [&lt;=]40 degrees C); Potentially life threatening (&gt;40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours [hrs]); Moderate(&gt;2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(&gt;=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.</description>
        <time_frame>Within 7 days after vaccination</time_frame>
        <population>Immunogenicity subset. Participants may be represented in more than 1 category. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pre-specified Systemic Events Within 7 Days After Vaccination</title>
          <description>Systemic events (fever, fatigue, headache, chills, rash, vomiting, decreased appetite, diarrhea, new generalized muscle/joint pain [new muscle/joint pain], aggravated generalized muscle/joint pain [aggravated muscle/joint pain], use of medication to treat pain/fever) reported using an e-diary. Fever scaled as Absent(&lt;38 degrees C); Mild(greater than or equal to [&gt;=]38 to &lt;38.5 degrees C); Moderate(&gt;=38.5 to &lt;39 degrees C); Severe(&gt;=39 to less than or equal to [&lt;=]40 degrees C); Potentially life threatening (&gt;40 degrees C). Fatigue, headache, new/aggravated muscle/joint pain scaled as Mild(no interference); Moderate(some interference); Severe(prevented routine activity). Vomiting scaled as Mild(1-2 times in 24 hours [hrs]); Moderate(&gt;2 times in 24 hrs); Severe(required intravenous hydration). Diarrhea scaled as Mild(2-3 loose stools in 24 hrs); Moderate(4-5 loose stools in 24 hrs); Severe(&gt;=6 loose stools in 24 hrs). Percentage of participants with systemic events were reported.</description>
          <population>Immunogenicity subset. Participants may be represented in more than 1 category. Here 'N' (number of participants analyzed) signifies participants with known values for any systemic event and 'n' signifies participants with known values for specified systemic event.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="907"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever: &gt;=38 to &lt;38.5 degrees C (n = 883, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.5" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=38.5 to &lt;39 degrees C (n = 881, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;=39 to =&lt;40 degrees C (n = 882, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.2" lower_limit="0.0" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever: &gt;40 degrees C (n = 882, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.3" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Mild (n = 892, 871)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" lower_limit="11.6" upper_limit="16.2"/>
                    <measurement group_id="O2" value="11.7" lower_limit="9.7" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Moderate (n = 886, 866)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="6.1" upper_limit="9.8"/>
                    <measurement group_id="O2" value="6.2" lower_limit="4.7" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue: Severe (n = 883, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.7" upper_limit="2.4"/>
                    <measurement group_id="O2" value="0.9" lower_limit="0.4" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Mild (n = 891, 870)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="10.9" upper_limit="15.4"/>
                    <measurement group_id="O2" value="13.1" lower_limit="10.9" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Moderate (n = 883, 868)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="3.8" upper_limit="6.9"/>
                    <measurement group_id="O2" value="3.8" lower_limit="2.6" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache: Severe (n = 881, 861)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.2" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.2" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills (n = 891, 866)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="7.6" upper_limit="11.5"/>
                    <measurement group_id="O2" value="8.4" lower_limit="6.7" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash (n = 882, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="2.2" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.3" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Mild (n = 881, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Moderate (n =881, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting: Severe (n = 881, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n = 886, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="3.9" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2.5" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Mild (n = 887, 868)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.7" upper_limit="6.7"/>
                    <measurement group_id="O2" value="7.7" lower_limit="6.0" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Moderate (n = 882, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.6" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.5" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea: Severe (n = 881, 862)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain: Mild (n = 894, 865)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="12.3" upper_limit="17.0"/>
                    <measurement group_id="O2" value="6.7" lower_limit="5.1" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain: Moderate (n = 886, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="4.4" upper_limit="7.6"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.8" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New muscle pain: Severe (n = 882, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0.1" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain: Mild (n = 886, 862)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="3.3" upper_limit="6.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.1" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain: Moderate (n = 885, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="3.7" upper_limit="6.7"/>
                    <measurement group_id="O2" value="2.8" lower_limit="1.8" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated muscle pain: Severe (n = 882, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.3" upper_limit="1.5"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.0" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain: Mild (n = 884, 862)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" lower_limit="3.6" upper_limit="6.6"/>
                    <measurement group_id="O2" value="3.9" lower_limit="2.7" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain: Moderate (n = 883, 864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="1.9" upper_limit="4.3"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.3" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New joint pain: Severe (n = 882, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain: Mild (n = 883, 861)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="1.4" upper_limit="3.5"/>
                    <measurement group_id="O2" value="1.7" lower_limit="1.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain: Moderate (n = 884, 862)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.1" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.6" lower_limit="1.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aggravated joint pain: Severe (n = 882, 860)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.1" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat pain (n = 887, 872)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="6.3" upper_limit="10.0"/>
                    <measurement group_id="O2" value="6.2" lower_limit="4.7" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat fever (n = 883, 863)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.1" upper_limit="4.6"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.8" upper_limit="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Who Died</title>
        <description>Deaths collected throughout the case acquisition period were presented.</description>
        <time_frame>From signing of informed consent form up to case acquisition period defined as accumulation of 130 VT cases (mean follow-up was 3.97 years)</time_frame>
        <population>Safety population included all participants who received study vaccine and who had any safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died</title>
          <description>Deaths collected throughout the case acquisition period were presented.</description>
          <population>Safety population included all participants who received study vaccine and who had any safety data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42237"/>
                <count group_id="O2" value="42255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test, 2-sided, was used to calculate the p-value for the difference between vaccine groups in percentages of participants.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.979</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition</title>
        <description>Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.</description>
        <time_frame>From 1 month after vaccination up to 6 months after vaccination</time_frame>
        <population>Immunogenicity subset included participants enrolled in the subset who received study vaccine, were able to complete e-diary and fulfilled other study procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC</title>
            <description>Participants received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Newly Diagnosed Chronic Medical Condition</title>
          <description>Percentage of participants with newly diagnosed chronic medical conditions (including autoimmune or neuroinflammatory disease) in the immunogenicity subset were reported as per planned analysis.</description>
          <population>Immunogenicity subset included participants enrolled in the subset who received study vaccine, were able to complete e-diary and fulfilled other study procedures.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1006"/>
                <count group_id="O2" value="1005"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Fisher exact test, 2-sided, was used to calculate the p-value for the difference between vaccine groups in percentages of participants.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.455</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety set (SAEs: Day 1 up to 1 month after vaccination); Immunogenicity subset (SAEs:1 month up to 6 month after vaccination; Other AEs: Day 1 up to 1 month after vaccination; pre-specified local reactions, systemic events:up to 7 days after vaccination)</time_frame>
      <desc>SAEs were collected up to 1 month after vaccination for safety set. For immunogenicity subset, other AEs were collected up to 1 month after vaccination and SAEs collected from 1 month up to 6 months after vaccination. Deaths collected throughout case acquisition period but reported as SAE only during SAE collection periods as per planned analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>13vPnC Safety Set</title>
          <description>All Participants who received a single 0.5 milliliter (mL) dose of 13-valent pneumococcal conjugate vaccine (13vPnC) intramuscular injection on Day 1, were assessed for serious adverse events (SAEs) from vaccination up to 1 month after vaccination. Safety set included all participants who received study vaccine and who had any safety data.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Safety Set</title>
          <description>All participants who received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1, were assessed for SAEs from vaccination up to 1 month after vaccination. Safety set included all participants who received study vaccine and who had any safety data.</description>
        </group>
        <group group_id="E3">
          <title>13vPnC Immunogenicity Subset</title>
          <description>Participants included in immunogenicity subset who received a single 0.5 mL dose of 13vPnC intramuscular injection on Day 1, were assessed for SAEs from 1 month after vaccination up to 6 months after vaccination and for Other adverse events (AEs) from vaccination up to 1 month after vaccination. Immunogenicity subset included participants enrolled in the subset who received study vaccine, were able to complete e-diary and fulfilled other study procedures.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Immunogenicity Subset</title>
          <description>Participants included in immunogenicity subset who received placebo matched to a single dose of 13vPnC intramuscular injection on Day 1, were assessed for SAEs from 1 month after vaccination up to 6 months after vaccination and for Other AEs from vaccination up to 1 month after vaccination. Immunogenicity subset included participants enrolled in the subset who received study vaccine, were able to complete e-diary and fulfilled other study procedures.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="314" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Implant site fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Corneal graft rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cholangitis suppurative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardiac valve replacement complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Kidney contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Mental status changes postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Post laminectomy syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Finger deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bladder adenocarcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Glioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hepatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Melanoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bile duct adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Renal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Acute disseminated encephalomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Radiculitis lumbosacral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Peripheral nerve lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="42255"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="363" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="315" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vaccination site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;=38 to &lt;38.5 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="883"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;=38.5 to &lt;39 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;=39 to =&lt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fever: &gt;40 degrees C</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="892"/>
                <counts group_id="E4" subjects_affected="102" subjects_at_risk="871"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="69" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="866"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Fatigue: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="883"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="863"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="116" subjects_at_risk="891"/>
                <counts group_id="E4" subjects_affected="114" subjects_at_risk="870"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="883"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Headache: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Chills</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="891"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="866"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Vomiting: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Decreased appetite</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="865"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="887"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="863"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Diarrhea: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="862"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New generalized muscle pain: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="130" subjects_at_risk="894"/>
                <counts group_id="E4" subjects_affected="58" subjects_at_risk="865"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New generalized muscle pain: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="863"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New generalized muscle pain: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated generalized muscle pain: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="862"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated generalized muscle pain: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="885"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="863"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated generalized muscle pain: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New generalized joint pain: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="884"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="862"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New generalized joint pain: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="883"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="864"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">New generalized joint pain: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated generalized joint pain: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="883"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated generalized joint pain: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="884"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="862"/>
              </event>
              <event>
                <sub_title vocab="Systemic Events">Aggravated generalized joint pain: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="860"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tinea barbae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Periorbital contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Traumatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Inclusion body myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Musculoskeletal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Blood blister</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Redness: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="888"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="888"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="884"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Swelling: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="859"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="330" subjects_at_risk="914"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="863"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="300" subjects_at_risk="913"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="861"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="886"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Pain: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="881"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement: Any</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="891"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="865"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement: Mild</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="888"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="863"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement: Moderate</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="883"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="860"/>
              </event>
              <event>
                <sub_title vocab="Local Reactions">Limitation of arm movement: Severe</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="882"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="861"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1005"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1006"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1005"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

